According
to the latest report published by Credence Research, Inc. “Actinic
Keratosis Market(Liquid Nitrogen Cryotherapy,
Surgical Therapy, 5-aminolevulinic acid (ALA), Methyl Aminolevulinate (MAL),
5-fluorouracil, Imiquimod, Ingenol Mebutate, Diclofenac Sodium, Chemical Peels
and Others) – Growth, Future Prospects and Competitive Analysis, 2016-2022,” the actinic
keratosis market was valued at USD 6,561.8 Mn in 2015 and is expected to reach
USD 8,909.7 Mn by 2022, with the market progressing at a CAGR 4.35%from
2016-2022.
Market
Insights
Actinic
keratosis (AK) is characterized by skin papules, macules or plaques resulting
from prolonged exposure to harmful UV exposure and can result in squamous cell
carcinoma. Risk of developing actinic keratosis increases with advancing age
and is particularly higher in men as against women. About 5-20% of patients
with actinic keratosis lesions develop malignant and potentially fatal squamous
cell carcinomas.
Browse
the full report Actinic Keratosis Market @ http://www.credenceresearch.com/report/actinic-keratosis-market
Among the various
treatment methods available, destructive therapies such as liquid nitrogen
cryotherapy and surgical therapy constitute the gold standard for AK treatment.
In 2015, cryotherapy was the most commonly sought treatment by clinicians.
However, better clinical results of photodynamic therapy and growing preference
for treatments based on drug-device combination have urged both caregivers and
patients to opt for novel treatment methods that offer both advanced efficacy,
aesthetic benefits and reduced risk of future malignancies. Topical
treatment is a prolonged treatment and comparatively more effective than other
treatments but patient compliance is the key issue that hinders the growth of
this segment. Photodynamic therapy is the fastest growing treatment throughout
the forecast period due to rising demand for non-invasive surgeries, and less
treatment sessions are the key factors expected to assist this market
North
America is the largest market for actinic keratosis treatment due to growing
prevalence of AK, better public awareness about occurrence of AK and associated
risk of squamous cell carcinoma. According to American Academy of Dermatology
(AAD), approximately 60% of the Americans aged 40 year or above, Actinic
Keratosis is predisposed to develop having at least 1 AK lesion. Actinic
keratosis is precursors of squamous cell cancer. U.S. held the largest share in
the actinic keratosis market in 2015 owing to current prevalence of actinic
keratosis in the region.Asia Pacific is the fastest growing market for AK
treatments. Australia has the highest prevalence of actinic keratosis ranging
between 40% to 60% in adult population. Growing awareness in the region and
rapid development in healthcare infrastructure and healthcare expenditure are
the key growth factors in Asia Pacific actinic keratosis market.
This
market is majorly driven by wide presence of generic drugs and is moderately
competitive. Photodynamic therapy market has developed a niche with methyl
aminolevulinate and aminolevulinic acid drugs. Galderma and DUSA
pharmaceuticals are the chief players in this space. Some of the major players
in the global actinic keratosis market are Tolmar Pharmaceuticals, Inc, DUSA
Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Aqua
Pharmaceuticals, LLC, Galderma SA, Perrigo Company plc, LEO Laboratories,
Apotex and others.
About Us:
Credence Research is a
worldwide market research and counseling firm that serves driving
organizations, governments, non-legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to
their execution and understand their most imperative objectives. Over almost a
century, we’ve manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
No comments:
Post a Comment